The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Open accessAbstract
The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic impact on human health1. Widespread community transmission has triggered stringent distancing measures with severe socio-economic consequences. Gaining control of the pandemic will depend on the interruption of transmission chains until vaccine-induced or naturally acquired protective herd immunity arises. However, approved antiviral treatments such as remdesivir and reconvalescent serum cannot be delivered orally2,3, making them poorly suitable for transmission control. We previously reported the development of an orally efficacious ribonucleoside analogue inhibitor of influenza viruses, MK-4482/EIDD-2801 (refs. 4,5), that was repurposed for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is currently in phase II/III clinical trials (NCT04405570 and NCT04405739). Here, we explored the efficacy of therapeutically administered MK-4482/EIDD-2801 to mitigate SARS-CoV-2 infection and block transmission in the ferret model, given that ferrets and related members of the weasel genus transmit the virus efficiently with minimal clinical signs6–9, which resembles the spread in the human young-adult population. We demonstrate high SARS-CoV-2 burden in nasal tissues and secretions, which coincided with efficient transmission through direct contact. Therapeutic treatment of infected animals with MK-4482/EIDD-2801 twice a day significantly reduced the SARS-CoV-2 load in the upper respiratory tract and completely suppressed spread to untreated contact animals. This study identified oral MK-4482/EIDD-2801 as a promising antiviral countermeasure to break SARS-CoV-2 community transmission chains. Treatment of SARS-CoV-2-infected ferrets with a nucleoside analogue (MK-4482/EIDD-2801) reduced the viral load in the upper respiratory tract and suppressed the spread of the virus to untreated ferrets. Therapeutic administration of MK-4482/EIDD-2801 may have the potential to break SARS-CoV-2 transmission chains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661 · cited 1×
“A virological study of hospitalized patients with COVID-19 has revealed that the average load of SARS-CoV-2 RNA copies detected in human sputum during the peak phase of infection was 7.0×10 6 (maximum 2.35×10 9 ) copies/ml 29 .”
InfluentialSusceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,911
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759
Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans
Oude Munnink, B. B., Sikkema, R. S., Nieuwenhuijse, D. F., Molenaar, R. J., Munger, E., Molenkamp, R., van der Spek, A., Tolsma, P., Rietveld, A., Brouwer, M., et al. (2021) · Science · doi:10.1126/science.abe5901 · Cited by 1,117
Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,071
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
Imai, M., Iwatsuki-Horimoto, K., Hatta, M., Loeber, S., Halfmann, P. J., Nakajima, N., Watanabe, T., Ujie, M., Takahashi, K., Ito, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009799117 · Cited by 1,021
RNA virus error catastrophe: Direct molecular test by using ribavirin
Crotty, S., Cameron, C. E., & Andino, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111085598 · Cited by 849
Infection of dogs with SARS-CoV-2
Sit, T. H. C., Brackman, C. J., Ip, S. M., Tam, K. W. S., Law, P. Y. T., To, E. M. W., Yu, V. Y. T., Sims, L. D., Tsang, D. N. C., Chu, D. K. W., et al. (2020) · Nature · doi:10.1038/s41586-020-2334-5 · Cited by 744
SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020
Oreshkova, N., Molenaar, R. J., Vreman, S., Harders, F., Oude Munnink, B. B., Hakze-van der Honing, R. W., Gerhards, N., Tolsma, P., Bouwstra, R., Sikkema, R. S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.23.2001005 · Cited by 702
Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis
Huang, I., & Pranata, R. (2020) · Journal of Intensive Care · doi:10.1186/s40560-020-00453-4 · Cited by 662
Cited by
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Kabinger, F., Stiller, C., Schmitzová, J., Dienemann, C., Kokic, G., Hillen, H. S., Höbartner, C., & Cramer, P. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00651-0 · Cited by 750
Fischer, W. A., Eron, J. J., Holman, W., Cohen, M. S., Fang, L., Szewczyk, L. J., Sheahan, T. P., Baric, R., Mollan, K. R., Wolfe, C. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7430 · Cited by 529
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Wahl, A., Gralinski, L. E., Johnson, C. E., Yao, W., Kovarova, M., Dinnon, K. H., Liu, H., Madden, V. J., Krzystek, H. M., De, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03312-w · Cited by 409
Painter, W. P., Holman, W., Bush, J. A., Almazedi, F., Malik, H., Eraut, N. C. J. E., Morin, M. J., Szewczyk, L. J., & Painter, G. R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02428-20 · Cited by 397
Metadata
- Authors
- Cox, R. M., Wolf, J. D., & Plemper, R. K.
- Venue
- Nature Microbiology
- Published
- 2020-12-03
- Volume
- 6
- Issue
- 1
- Pages
- 11-18
- ISSN
- 2058-5276 (ISSN-L)
- OpenAlex
- W3110209099
- Cited by
- 387
- References
- 34
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. https://app.cochat.ai/papers/10.1038/s41564-020-00835-2
- The paper
- Cox, R. M., Wolf, J. D., & Plemper, R. K. (2020). Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nature Microbiology. https://doi.org/10.1038/s41564-020-00835-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.